CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...